$0 is the total value of RiverVest Venture Management LLC's 0 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2022 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Allakos, Inc. | 12 | Q3 2023 | 88.4% |
| Spruce Bioscience, Inc. | 12 | Q3 2023 | 16.4% |
| Vapotherm, Inc. | 12 | Q3 2023 | 6.0% |
| Mirum Pharmaceuticals, Inc. | 11 | Q2 2023 | 54.9% |
| Reneo Pharmaceuticals, Inc. Fund 4 | 10 | Q3 2023 | 47.7% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 16.5% |
| Otonomy, Inc. | 1 | Q4 2020 | 0.4% |
View RiverVest Venture Management LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-08 |
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-10-30 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-02 |
| 13F-HR | 2022-02-07 |
View RiverVest Venture Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.